̽��ֱ�� of Cambridge - Cambridge Nanoscience Centre

10 Cambridge spinouts changing the story of cancer

skbf2 — Thu, 17 Oct 2024 12:57:43 +0000

10 Cambridge spinouts on putting their research into practice to improve outcomes for cancer patients - and why Cambridge is a great place to do this.

New graphene based inks for high-speed manufacturing of printed electronics

sc604 — Mon, 19 Oct 2015 10:38:54 +0000

A low-cost, high-speed method for printing graphene inks using a conventional roll-to-roll printing process, like that used to print newspapers and crisp packets, could open up a wide range of practical applications, including inexpensive printed electronics, intelligent packaging and disposable sensors.

Developed by researchers at the ̽��ֱ�� of Cambridge in collaboration with Cambridge-based technology company Novalia, the method allows graphene and other electrically conducting materials to be added to conventional water-based inks and printed using typical commercial equipment, the first time that graphene has been used for printing on a large-scale commercial printing press at high speed.

Graphene is a two-dimensional sheet of carbon atoms, just one atom thick. Its flexibility, optical transparency and electrical conductivity make it suitable for a wide range of applications, including printed electronics. Although numerous laboratory prototypes have been demonstrated around the world, widespread commercial use of graphene is yet to be realised.

“We are pleased to be the first to bring graphene inks close to real-world manufacturing. There are lots of companies that have produced graphene inks, but none of them has done it on a scale close to this,” said Dr Tawfique Hasan of the Cambridge Graphene Centre (CGC), who developed the method. “Being able to produce conductive inks that could effortlessly be used for printing at a commercial scale at a very high speed will open up all kinds of different applications for graphene and other similar materials.”

“This method will allow us to put electronic systems into entirely unexpected shapes,” said Chris Jones of Novalia. “It’s an incredibly flexible enabling technology.”

Hasan’s method, developed at the ̽��ֱ��’s Nanoscience Centre, works by suspending tiny particles of graphene in a ‘carrier’ solvent mixture, which is added to conductive water-based ink formulations. ̽��ֱ��ratio of the ingredients can be adjusted to control the liquid’s properties, allowing the carrier solvent to be easily mixed into a conventional conductive water-based ink to significantly reduce the resistance. ̽��ֱ��same method works for materials other than graphene, including metallic, semiconducting and insulating nanoparticles.

Currently, printed conductive patterns use a combination of poorly conducting carbon with other materials, most commonly silver, which is expensive. Silver-based inks cost £1000 or more per kilogram, whereas this new graphene ink formulation would be 25 times cheaper. Additionally, silver is not recyclable, while graphene and other carbon materials can easily be recycled. ̽��ֱ��new method uses cheap, non-toxic and environmentally friendly solvents that can be dried quickly at room temperature, reducing energy costs for ink curing. Once dry, the ‘electric ink’ is also waterproof and adheres to its substrate extremely well.

̽��ֱ��graphene-based inks have been printed at a rate of more than 100 metres per minute, which is in line with commercial production rates for graphics printing, and far faster than earlier prototypes. Two years ago, Hasan and his colleagues produced a prototype of a transparent and flexible piano using graphene-based inks, which took between six and eight hours to make. Through the use of this new ink, more versatile devices on paper or plastic can be made at a rate of 300 per minute, at a very low cost. Novalia has also produced a printed DJ deck and an interactive poster, which functions as a drum kit using the same method.

Hasan and PhD students Guohua Hu, Richard Howe and Zongyin Yang of the Hybrid Nanomaterials Engineering group at CGC, in collaboration with Novalia, tested the method on a typical commercial printing press, which required no modifications in order to print with the graphene ink. In addition to the new applications the method will open up for graphene, it could also initiate entirely new business opportunities for commercial graphics printers, who could diversify into the electronics sector.

“ ̽��ֱ��UK, and the Cambridge area in particular, has always been strong in the printing sector, but mostly for graphics printing and packaging,” said Hasan, a Royal Academy of Engineering Research Fellow and a ̽��ֱ�� Lecturer in the Engineering Department. “We hope to use this strong local expertise to expand our functional ink platform. In addition to cheaper printable electronics, this technology opens up potential application areas such as smart packaging and disposable sensors, which to date have largely been inaccessible due to cost.”

In the short to medium term, the researchers hope to use their method to make printed, disposable biosensors, energy harvesters and RFID tags.

̽��ֱ��research was supported by grants from the Engineering and Physical Sciences Research Council's Impact Acceleration Account and a Royal Academy of Engineering Research Fellowship. ̽��ֱ��technology is being commercialised by Cambridge Enterprise, the ̽��ֱ��’s commercialisation arm.

A low-cost, high-speed method for printing electronics using graphene and other conductive materials could open up a wide range of commercial applications.

Being able to produce conductive inks that could effortlessly be used for printing at a commercial scale at a very high speed will open up all kinds of different applications for graphene and other similar materials

Tawfique Hasan

Roll-to-roll printing of graphene ink

̽��ֱ��text in this work is licensed under a Creative Commons Attribution 4.0 International License. For image use please see separate credits above.

Yes

“Trojan horse” treatment could beat brain tumours

tdk25 — Wed, 13 Aug 2014 07:00:12 +0000

A “Trojan horse” treatment for an aggressive form of brain cancer, which involves using tiny nanoparticles of gold to kill tumour cells, has been successfully tested by scientists.

̽��ֱ��ground-breaking technique could eventually be used to treat glioblastoma multiforme, which is the most common and aggressive brain tumour in adults, and notoriously difficult to treat. Many sufferers die within a few months of diagnosis, and just six in every 100 patients with the condition are alive after five years.

̽��ֱ��research involved engineering nanostructures containing both gold and cisplatin, a conventional chemotherapy drug. These were released into tumour cells that had been taken from glioblastoma patients and grown in the lab.

Once inside, these “nanospheres” were exposed to radiotherapy. This caused the gold to release electrons which damaged the cancer cell’s DNA and its overall structure, thereby enhancing the impact of the chemotherapy drug.

̽��ֱ��process was so effective that 20 days later, the cell culture showed no evidence of any revival, suggesting that the tumour cells had been destroyed.

While further work needs to be done before the same technology can be used to treat people with glioblastoma, the results offer a highly promising foundation for future therapies. Importantly, the research was carried out on cell lines derived directly from glioblastoma patients, enabling the team to test the approach on evolving, drug-resistant tumours.

̽��ֱ��study was led by Mark Welland, Professor of Nanotechnology at the Department of Engineering and a Fellow of St John’s College, ̽��ֱ�� of Cambridge, and Dr Colin Watts, a clinician scientist and honorary consultant neurosurgeon at the Department of Clinical Neurosciences. Their work is reported in the Royal Society of Chemistry journal, Nanoscale.

“ ̽��ֱ��combined therapy that we have devised appears to be incredibly effective in the live cell culture,” Professor Welland said. “This is not a cure, but it does demonstrate what nanotechnology can achieve in fighting these aggressive cancers. By combining this strategy with cancer cell-targeting materials, we should be able to develop a therapy for glioblastoma and other challenging cancers in the future.”

To date, glioblastoma multiforme (GBM) has proven very resistant to treatments. One reason for this is that the tumour cells invade surrounding, healthy brain tissue, which makes the surgical removal of the tumour virtually impossible.

Used on their own, chemotherapy drugs can cause a dip in the rate at which the tumour spreads. In many cases, however, this is temporary, as the cell population then recovers.

“We need to be able to hit the cancer cells directly with more than one treatment at the same time” Dr Watts said. “This is important because some cancer cells are more resistant to one type of treatment than another. Nanotechnology provides the opportunity to give the cancer cells this ‘double whammy’ and open up new treatment options in the future.”

In an effort to beat tumours more comprehensively, scientists have been researching ways in which gold nanoparticles might be used in treatments for some time. Gold is a benign material which in itself poses no threat to the patient, and the size and shape of the particles can be controlled very accurately.

When exposed to radiotherapy, the particles emit a type of low energy electron, known as Auger electrons, capable of damaging the diseased cell’s DNA and other intracellular molecules. This low energy emission means that they only have an impact at short range, so they do not cause any serious damage to healthy cells that are nearby.

In the new study, the researchers first wrapped gold nanoparticles inside a positively charged polymer, polyethylenimine. This interacted with proteins on the cell surface called proteoglycans which led to the nanoparticles being ingested by the cell.

Once there, it was possible to excite it using standard radiotherapy, which many GBM patients undergo as a matter of course. This released the electrons to attack the cell DNA.

While gold nanospheres, without any accompanying drug, were found to cause significant cell damage, treatment-resistant cell populations did eventually recover several days after the radiotherapy. As a result, the researchers then engineered a second nanostructure which was suffused with cisplatin.

̽��ֱ��chemotherapeutic effect of cisplatin combined with the radiosensitizing effect of gold nanoparticles resulted in enhanced synergy enabling a more effective cellular damage. Subsequent tests revealed that the treatment had reduced the visible cell population by a factor of 100 thousand, compared with an untreated cell culture, within the space of just 20 days. No population renewal was detected.

̽��ֱ��researchers believe that similar models could eventually be used to treat other types of challenging cancers. First, however, the method itself needs to be turned into an applicable treatment for GBM patients. This process, which will be the focus of much of the group’s forthcoming research, will necessarily involve extensive trials. Further work needs to be done, too, in determining how best to deliver the treatment and in other areas, such as modifying the size and surface chemistry of the nanomedicine so that the body can accommodate it safely.

Sonali Setua, a PhD student who worked on the project, said: “It was hugely satisfying to chase such a challenging goal and to be able to target and destroy these aggressive cancer cells. This finding has enormous potential to be tested in a clinical trial in the near future and developed into a novel treatment to overcome therapeutic resistance of glioblastoma.”

Welland added that the significance of the group’s results to date was partly due to the direct collaboration between nanoscientists and clinicians. “It made a huge difference, as by working with surgeons we were able to ensure that the nanoscience was clinically relevant,” he said. “That optimises our chances of taking this beyond the lab stage, and actually having a clinical impact.”

̽��ֱ��full research paper can be found at: http://dx.doi.org/10.1039/c4nr03693j

A smart technology which involves smuggling gold nanoparticles into brain cancer cells has proven highly effective in lab-based tests.

By combining this strategy with cancer cell-targeting materials, we should be able to develop a therapy for glioblastoma and other challenging cancers in the future

Mark Welland

M Welland

A cancer cell containing the nanoparticles. ̽��ֱ��nanoparticles are coloured green, and have entered the nucleus, which is the area in blue

̽��ֱ��text in this work is licensed under a Creative Commons Licence. If you use this content on your site please link back to this page. For image rights, please see the credits associated with each individual image.

Yes